Teprotumumab

Drug Profile

Teprotumumab

Alternative Names: HZN 001; Insulin-like-growth-factor-1-receptor-antagonist-antibody-River-Vision-Development; R 1507; RG 1507; RO-4858696; RV 001-River-Vision

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Genmab; Roche
  • Developer Horizon Pharma; Roche
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Insulin-like growth factor-I receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Graves ophthalmopathy
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Graves ophthalmopathy
  • Phase I Diabetic macular oedema
  • Discontinued Advanced breast cancer; Hodgkin's disease; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Sarcoma; Solid tumours

Most Recent Events

  • 08 May 2017 Teprotumumab receives Breakthrough Therapy status for Graves ophthalmopathy in USA before May 2017
  • 08 May 2017 Teprotumumab receives Fast Track designation for Graves ophthalmopathy [IV,Infusion] in USA before May 2017
  • 08 May 2017 Horizon plans a Phase III trial for Graves ophthalmopathy
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top